Show simple item record

dc.contributor.author
Orlewska, Katarzyna
dc.contributor.author
Bogusz, Krzysztof
dc.contributor.author
Podlecka-Piętowska, Aleksandra
dc.contributor.author
Nojszewska, Monika
dc.contributor.author
Markiewicz, Mirosław
dc.contributor.author
Liwoch, Robert
dc.contributor.author
Orlewski, Pawel
dc.contributor.author
Śliwczyński, Andrzej
dc.contributor.author
Zakrzewska-Pniewska, Beata
dc.contributor.author
Snarski, Emilian
dc.date.accessioned
2021-04-21T15:39:39Z
dc.date.available
2021-04-20T03:22:47Z
dc.date.available
2021-04-21T15:39:39Z
dc.date.issued
2021-09
dc.identifier.other
10.1016/j.vhri.2020.10.008
en_US
dc.identifier.uri
http://hdl.handle.net/20.500.11850/479437
dc.description.abstract
Objectives To provide real-world data on the impact of autologous hematopoietic stem cell transplantation (AHSCT) on treatment costs of patients with multiple sclerosis (MS) in Poland. Methods Medical data of 105 patients who underwent AHSCT in the years 2011 to 2016 were obtained from the National Health Fund (NHF) database. Treatment costs were calculated from the public payer’s perspective per patient-year for the total available period as well as 12 months before and after AHSCT. The statistical analysis was performed using MATLAB 2016b. Results Mean treatment-related costs covered by the NHF per patient-year before and after the transplantation were €4314.9 and €1188.8 , respectively. The average cost of disease-modifying drugs per patient was reduced from €2497.9/year before to €65.3/year after AHSCT. Conclusions Although the initial cost of AHSCT is high, the costs involving AHSCT and post-AHSCT treatment could, according to our analysis, pay off in 3.9 years, when compared to the costs of disease-modifying drug therapy in aggressive MS. The study provides evidence that the AHSCT can lead to significant savings in treatment costs of aggressive MS from the public payer’s perspective. © 2021 Elsevier
en_US
dc.language.iso
en
en_US
dc.publisher
Elsevier
en_US
dc.subject
Autologous hematopoietic stem cell transplantation
en_US
dc.subject
Multiple sclerosis
en_US
dc.subject
Real-world data
en_US
dc.title
Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study
en_US
dc.type
Journal Article
dc.date.published
2021-04-14
ethz.journal.title
Value in Health Regional Issues
ethz.journal.volume
25
en_US
ethz.pages.start
104
en_US
ethz.pages.end
107
en_US
ethz.identifier.wos
ethz.identifier.scopus
ethz.publication.place
Amsterdam
en_US
ethz.publication.status
published
en_US
ethz.date.deposited
2021-04-20T03:23:01Z
ethz.source
SCOPUS
ethz.eth
yes
en_US
ethz.availability
Metadata only
en_US
ethz.rosetta.installDate
2021-04-21T15:39:50Z
ethz.rosetta.lastUpdated
2022-03-29T06:42:05Z
ethz.rosetta.versionExported
true
ethz.COinS
ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=Impact%20of%20Immunoablation%20and%20Autologous%20Hematopoietic%20Stem%20Cell%20Transplantation%20(AHSCT)%20on%20Treatment%20Cost%20of%20Multiple%20Sclerosis:%20Real-Wor&rft.jtitle=Value%20in%20Health%20Regional%20Issues&rft.date=2021-09&rft.volume=25&rft.spage=104&rft.epage=107&rft.au=Orlewska,%20Katarzyna&Bogusz,%20Krzysztof&Podlecka-Pi%C4%99towska,%20Aleksandra&Nojszewska,%20Monika&Markiewicz,%20Miros%C5%82aw&rft.genre=article&rft_id=info:doi/10.1016/j.vhri.2020.10.008&
 Search print copy at ETH Library

Files in this item

FilesSizeFormatOpen in viewer

There are no files associated with this item.

Publication type

Show simple item record